15th July 2010, paclitaxel APIs(active pharmaceutical ingredients) was called off export rebate from China customs rebate list for new round of economy adjustment and partial reasons of environment protection consideration. Such act will affect export situation for China as one of the most important paclitaxel APIs countries, exporting about 14% of its domestic output according to the data from China Customs. However, the influence of this seems slim on China paclitaxel injection industry, and the market is still stable for a period, according to the survey of CCM International Limited, Chinese market research firm.
A market research report published in late July by CCM International, reports that the cancellation of paclitaxel APIs export rebate may increase the supply in domestic market, but the injection market has had no sharp reaction so far. Actually, such APIs had some adjustments on export rebate in decade.
With regard to this injection market, policies and pharmaceutical distribution situation are the two key influencing factors.
"By the end of Jun. 2010, many standards about environmental protection, production safety and application safety had been promulgated in China. Chinese government has strengthened pollution and quality control in paclitaxel industry to safeguard public health and eco-balance." Told by CCM report. Healthcare reform policies issued by China government in 2009, which aim at relieving economic burden of patients, may increase anticancer drug market consumption.
Considering anticancer drug sales market, several substitutes grow rapidly, for instance docetaxel had higher growth rate comparing with pacalitaxel injection about 7% growth rate in 2009. Paclitaxel injection got slower growth rate in these years. The paclitaxel injection production values had reached USD67.21 million for China in 2009, account for 10% of total in world. And the injection domestic market shares were accounted for by domestic products, above 80%, the rest, mainly shared by Bristol-Myers Squibb (Taxol) and Mayne Pharma Pty Ltd (Anzatax). And both of production and sales value figures, will be higher in the next five years forecasted by CCM.
About this market share, Abraxis BioScience had launched his ABRAXANE in June 2009 in China, which will give sign for foreign companies that want to share this market, and totally boost paclitaxel injection industry. However, for these companies, the circulation and distribution platform situation should not be omitted. "Paclitaxel injection has to get into hospitals through the pharmaceutical distribution companies and medicine bidding and purchasing platforms." Such platforms which less acquaintance in first-trail companies are highlighted parts in CCM report.
China paclitaxel injection industry has witnessed significant development from 2005～2009, it's estimated to go far in the next five years, as more companies will be involved in the near future.
About CCM
CCM is dedicated to market research in China, Asia-Pacific Rim and global market. With a staff of more than 150 dedicated highly-educated professionals. CCM offers Market Data, Analysis, Reports, Newsletters, Buyer-Trader Information, Import/Export Analysis all through its new proprietary product ValoTracer.
Please visit http://www.cnchemicals.com for more information or contact econtact@cnchemicals.com
CCM International, Ltd.
Guangzhou CCM Information Science & Technology Co, Ltd.
17th Floor, Huihua Commercial & Trade Mansion No, 80 Xianlie Zhong Road, Guangzhou 510070, China